HeyJaredTed Bosworth
- Indexed articles, last 90 days
- 19
- Latest publication
- Sep 17, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 7, 2026
Latest articles
Mild Phenotype Eliminated in New HF Guidelines (opens the original)
Read excerpt
The new heart failure (HF) guidelines from the European Society of Cardiology (ESC) introduce new terminology, offer a new organization of therapies along the continuum of progression, and add greater emphasis to treating disease at its earliest stages. Among the most notable changes, the mildly reduced phenotype of HF has been eliminated. That leaves just two phenotypes: The preserved function phenotype retains the definition of a left ventricular ejection fraction (LVEF) of 50% or greater, and
Alopecia Areata Consensus Statement Recommends First-Line Rx (opens the original)
Read excerpt
A 6-month trial of oral JAK inhibitors has been identified as the primary first-line treatment for severe alopecia areata (AA) in the newly published and first-ever consensus statement to guide treatment of this condition. The consensus statement placed treatment options, including JAK inhibitors, into an evidence-based context for controlling AA in its severest form, according to the senior author, Arash Mostaghimi, MD, MPA, MPH, associate professor of dermatology at Harvard University in Cambr
Functional Angio Wins in Multivessel STEMI (opens the original)
Read excerpt
MUNICH — Despite fewer lesions being treated, complete revascularization of nonculprit lesions with functional coronary angiography was associated with better outcomes than with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease, according to results from the AIR-STEMI trial. Moving beyond visual estimation alone, “this approach brings complete revascularization closer to precision medicine by treating the lesions that matter whil
Prasugrel Falls Short as Default P2Y12 Inhibitor for ACS (opens the original)
Read excerpt
MUNICH — In the SWITCH-SWEDEHEART trial of more than 17,000 patients with acute coronary syndrome (ACS), prasugrel did not appear superior to ticagrelor for preventing major cardiovascular events. Although bleeding rates were lower during the periods when patients were treated with a prasugrel-first policy, “protection against major events was similar with both strategies in this unselected population,” said principal investigator Elmir Omerovic, MD, PhD, a professor of cardiology at Sahlgrenska
Sequencing of TAVI Before PCI Found to be Noninferior (opens the original)
Read excerpt
MUNICH — In patients with an indication for a percutaneous coronary intervention (PCI) and a transcatheter aortic valve implantation (TAVI), outcomes are similar whether TAVI is performed before PCI or the other way around, according to the first major randomized trial to address this question. Guidelines recommend sequential PCI and TAVI for those who need both, and PCI is widely performed first, the researchers said. In the study designed to test the noninferiority of a TAVI-first strategy, 22
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.